Market Cap 45.63M
Revenue (ttm) 0.00
Net Income (ttm) -2.44M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 49,400
Avg Vol 149,208
Day's Range N/A - N/A
Shares Out 34.83M
Stochastic %K 78%
Beta N/A
Analysts Sell
Price Target $25.00

Company Profile

Jupiter Neurosciences, Inc., a clinical stage research and development pharmaceutical company, develops resveratrol platform products for the treatment of neuroinflammation. The company develops JNS101, which is in Phase II trial for the treatment of Friedreich's Ataxia, a rare inherited disease that causes damage to the nervous system, as well as mobility dysfunctions; and JNS108 that is in Phase II trial for treating mild cognitive impairment/early Alzheimer's disease. It is also involved in t...

Industry: Biotechnology
Sector: Healthcare
Phone: 561 406 6154
Address:
1001 North US Highway 1, Suite 504, Jupiter, United States
Ichigodoran
Ichigodoran Nov. 14 at 5:22 PM
$JUNS Company website : https://jupiterneurosciences.com/
0 · Reply
Thebullrun
Thebullrun Nov. 14 at 3:53 PM
$JUNS Cel-Sci #CVM #NYSE (head and neck cancer) and Jupiter Neurosciences #JUNS #NASDAQ (Parkinson's Disease & Alzheimer's disease) are doing some great things for Humanity! Learn more about them below. #Biotech “Let’s Search and find the cure!” #JUNS - https://jupiterneurosciences.com/ #CVM - http://www.cel-sci.com/
0 · Reply
Ichigodoran
Ichigodoran Nov. 14 at 3:45 PM
$JUNS Jupiter Neurosciences Enters into Agreements for up to $20 Million in Flexible Financing https://www.globenewswire.com/news-release/2025/10/27/3174574/0/en/Jupiter-Neurosciences-Enters-into-Agreements-for-up-to-20-Million-in-Flexible-Financing.html
0 · Reply
Thebullrun
Thebullrun Nov. 14 at 3:31 PM
$JUNS #JUNS #NASDAQ Jupiter Neurosciences Receives FDA Clearance of IND Application to Initiate Phase 2a Clinical Trial of JOTROL™ in Parkinson’s Disease https://youtu.be/rs65rro_o8Y?si=xS2F6dL4JwdSxFNf https://finance.yahoo.com/news/jupiter-neurosciences-receives-fda-clearance-133000472.html
0 · Reply
Thebullrun
Thebullrun Nov. 14 at 3:28 PM
$JUNS **Exciting news from the biotech world! Jupiter Neurosciences, Inc. (#JUNS on #NASDAQ), a clinical-stage pharmaceutical company focused on addressing neuroinflammation and promoting healthy aging, has just received #FDA Clearance for its IND application to kick off a Phase 2a clinical trial of #JOTROL™ in Parkinson’s disease. JOTROL is their patented resveratrol-based platform that targets neuroinflammation and mitochondrial dysfunction, offering over nine times the bioavailability of traditional #resveratrol without the usual GI side effects. Preclinical data showed promising neuroprotective effects, improving motor functions in Parkinson’s models, and Phase 1 trials confirmed strong safety and bioavailability. The trial will assess safety, tolerability, and PK/PD in patients, with enrollment starting early 2026— a big step toward potential disease-modifying treatments for the 10M+ people affected by Parkinson’s worldwide.
0 · Reply
JohnHarden
JohnHarden Nov. 14 at 2:41 PM
$JUNS Jupiter Neurosciences Receives FDA Clearance of IND Application to Initiate Phase 2a Clinical Trial of JOTROL™ in Parkinson’s Disease https://www.stocktitan.net/news/JUNS/jupiter-neurosciences-receives-fda-clearance-of-ind-application-to-fdlwt0buzo3f.html
0 · Reply
Ichigodoran
Ichigodoran Nov. 14 at 1:36 PM
$JUNS Jupiter Neurosciences Receives FDA Clearance of IND Application to Initiate Phase 2a Clinical Trial of JOTROL™ in Parkinson’s Disease https://finance.yahoo.com/news/jupiter-neurosciences-receives-fda-clearance-133000472.html
0 · Reply
Thebullrun
Thebullrun Nov. 14 at 10:29 AM
$JUNS this one looks great! Rock n Roll!
0 · Reply
Thenew52
Thenew52 Nov. 6 at 3:32 AM
$JUNS If I were you, I'd buy it; JUNS is on sale.
0 · Reply
prismmarketview
prismmarketview Nov. 5 at 8:57 PM
(NASDAQ: $JUNS) #jupiterneuro has received FDA clearance for its IND application to start a Phase 2a clinical trial of JOTROL™, a resveratrol-based drug targeting neuroinflammation in Parkinson’s disease, with patient enrollment expected to begin in early 2026. The trial will primarily assess safety and tolerability, with additional evaluations of pharmacokinetics and pharmacodynamics. This marks a key step forward for the company and Parkinson's research. https://prismmarketview.com/jupiter-neurosciences-secures-fda-clearance-for-ind-of-jotrol-in-parkinsons-disease-phase-2a-trial/
0 · Reply
Latest News on JUNS
Ichigodoran
Ichigodoran Nov. 14 at 5:22 PM
$JUNS Company website : https://jupiterneurosciences.com/
0 · Reply
Thebullrun
Thebullrun Nov. 14 at 3:53 PM
$JUNS Cel-Sci #CVM #NYSE (head and neck cancer) and Jupiter Neurosciences #JUNS #NASDAQ (Parkinson's Disease & Alzheimer's disease) are doing some great things for Humanity! Learn more about them below. #Biotech “Let’s Search and find the cure!” #JUNS - https://jupiterneurosciences.com/ #CVM - http://www.cel-sci.com/
0 · Reply
Ichigodoran
Ichigodoran Nov. 14 at 3:45 PM
$JUNS Jupiter Neurosciences Enters into Agreements for up to $20 Million in Flexible Financing https://www.globenewswire.com/news-release/2025/10/27/3174574/0/en/Jupiter-Neurosciences-Enters-into-Agreements-for-up-to-20-Million-in-Flexible-Financing.html
0 · Reply
Thebullrun
Thebullrun Nov. 14 at 3:31 PM
$JUNS #JUNS #NASDAQ Jupiter Neurosciences Receives FDA Clearance of IND Application to Initiate Phase 2a Clinical Trial of JOTROL™ in Parkinson’s Disease https://youtu.be/rs65rro_o8Y?si=xS2F6dL4JwdSxFNf https://finance.yahoo.com/news/jupiter-neurosciences-receives-fda-clearance-133000472.html
0 · Reply
Thebullrun
Thebullrun Nov. 14 at 3:28 PM
$JUNS **Exciting news from the biotech world! Jupiter Neurosciences, Inc. (#JUNS on #NASDAQ), a clinical-stage pharmaceutical company focused on addressing neuroinflammation and promoting healthy aging, has just received #FDA Clearance for its IND application to kick off a Phase 2a clinical trial of #JOTROL™ in Parkinson’s disease. JOTROL is their patented resveratrol-based platform that targets neuroinflammation and mitochondrial dysfunction, offering over nine times the bioavailability of traditional #resveratrol without the usual GI side effects. Preclinical data showed promising neuroprotective effects, improving motor functions in Parkinson’s models, and Phase 1 trials confirmed strong safety and bioavailability. The trial will assess safety, tolerability, and PK/PD in patients, with enrollment starting early 2026— a big step toward potential disease-modifying treatments for the 10M+ people affected by Parkinson’s worldwide.
0 · Reply
JohnHarden
JohnHarden Nov. 14 at 2:41 PM
$JUNS Jupiter Neurosciences Receives FDA Clearance of IND Application to Initiate Phase 2a Clinical Trial of JOTROL™ in Parkinson’s Disease https://www.stocktitan.net/news/JUNS/jupiter-neurosciences-receives-fda-clearance-of-ind-application-to-fdlwt0buzo3f.html
0 · Reply
Ichigodoran
Ichigodoran Nov. 14 at 1:36 PM
$JUNS Jupiter Neurosciences Receives FDA Clearance of IND Application to Initiate Phase 2a Clinical Trial of JOTROL™ in Parkinson’s Disease https://finance.yahoo.com/news/jupiter-neurosciences-receives-fda-clearance-133000472.html
0 · Reply
Thebullrun
Thebullrun Nov. 14 at 10:29 AM
$JUNS this one looks great! Rock n Roll!
0 · Reply
Thenew52
Thenew52 Nov. 6 at 3:32 AM
$JUNS If I were you, I'd buy it; JUNS is on sale.
0 · Reply
prismmarketview
prismmarketview Nov. 5 at 8:57 PM
(NASDAQ: $JUNS) #jupiterneuro has received FDA clearance for its IND application to start a Phase 2a clinical trial of JOTROL™, a resveratrol-based drug targeting neuroinflammation in Parkinson’s disease, with patient enrollment expected to begin in early 2026. The trial will primarily assess safety and tolerability, with additional evaluations of pharmacokinetics and pharmacodynamics. This marks a key step forward for the company and Parkinson's research. https://prismmarketview.com/jupiter-neurosciences-secures-fda-clearance-for-ind-of-jotrol-in-parkinsons-disease-phase-2a-trial/
0 · Reply
benzinga
benzinga Nov. 5 at 8:08 PM
Jupiter Neurosciences Brings Its Brain Health Expertise To The Masses With Nugevia – And A Range Of Celebs From Athletes To Scientists Are Customers $JUNS https://www.benzinga.com/partner/biotech/25/11/48654189/jupiter-neurosciences-brings-its-brain-health-expertise-to-the-masses-with-nugevia-and-a-range-of
0 · Reply
Waterwing
Waterwing Nov. 5 at 7:39 PM
$JUNS added...
0 · Reply
DarrylEvans691
DarrylEvans691 Nov. 5 at 4:46 PM
$JUNS maintains neutral sentiment. AITX’s diversified AI-driven product range continues to attract clients seeking automation and safety optimization.
0 · Reply
leon_dedrick
leon_dedrick Nov. 5 at 1:39 PM
$JUNS Should be the biggest mover today with this news......
1 · Reply
Stock_Catcher
Stock_Catcher Nov. 5 at 1:34 PM
$JUNS Jupiter Neurosciences Receives FDA Clearance of IND Application to Initiate Phase 2a Clinical Trial of JOTROL™ in Parkinson’s Disease
1 · Reply
Thenew52
Thenew52 Oct. 29 at 2:24 PM
$JUNS You're a fool if you sell your shares cheap. They haven't diluted anything; it was a loan they can repay later with cash or shares at a price of $1.50, but nothing more. People have bought shares of companies that dilute up to 100 million shares in less than a year, but here, for a simple loan, are they going to sell cheap? When it reaches $4.X or more, that's when they'll want to buy again, and that's when it will keep going up and up. I'll sell with thousands in profit, and you'll buy high and end up waiting for it to go up to $10 or more.
1 · Reply
MB755
MB755 Oct. 27 at 12:55 PM
$JUNS 6$ million at 1.5
1 · Reply
MB755
MB755 Oct. 27 at 12:55 PM
$JUNS offering
0 · Reply
qbtsrycey
qbtsrycey Oct. 13 at 2:03 PM
$JUNS no word on my Nugevia MND pre-order yet - mmmm, should I worry?
1 · Reply
BagSniper_9
BagSniper_9 Oct. 5 at 8:51 AM
$JUNS Financial services micro-cap. No clear pattern. Illiquid conditions. Avoid.
1 · Reply
Thenew52
Thenew52 Oct. 2 at 1:36 AM
$JUNS I've said it before and I'll say it now, this is buy and hold until at least October/November, I'm not leaving here until it hits $3 a share and you shouldn't leave until it hits that either.
1 · Reply
SPYmyQQQ
SPYmyQQQ Oct. 1 at 5:01 PM
💊 🚀 $JUNS up ⬆️29.58% since our entry $1.42 on Sep 23, 2025 👉 FREE TRIAL! Check bio. ALL signals Time stamped. NO B.S.!
0 · Reply